6 core challenges that researchers must consider as the race to create models that are ever closer to real human embryos heats up.

Premature ovarian insufficiency (POI) affects 1–3% of women and has limited treatment options. Researchers report that ...

KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, su ...

Meet Ember and Echo. Born just three days apart in February 2025, they were the first African penguin chicks to hatch at the ...

Degraded natural wealth is not just an environmental problem, it is also an economic liability. But achieving economic growth without harming the environment is not only possible but has already been ...

History feels permanent, and after the fact, it is. But conditions are fluid in real time. Idaho wasn’t destined to be the ...

Blueprint Medicines, a Sanofi company, today announced AYVAKIT(R) (avapritinib) data showing clinically meaningful outcomes and a w ...

Premature ovarian insufficiency (POI) is a clinically significant cause of infertility that affects between 1 to 3% of women of childbearing age ...

Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the ...

Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...

Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of ...